{
    "topic": "opioid_crisis",
    "source": "Mother Jones",
    "bias": 0,
    "url": "https://www.motherjones.com/politics/2020/03/good-news-the-federal-government-just-made-it-a-whole-lot-easier-to-access-opioid-addiction-treatment/",
    "title": "Good News: The Federal Government Just Made It a Whole Lot Easier to Access Opioid Addiction Treatment",
    "date": "",
    "authors": "Julia Lurie, Kevin Drum, Inae Oh, Dan Friedman, Will Peischel, Kiera Butler, Fernanda Echavarri, Laura Thompson, David Corn, Aj Vicens",
    "content": "For the hundreds of thousands of Americans who have to visit clinics for daily doses of opioid addiction medication , social distancing is nearly impossible . But on Tuesday , the federal government eased some of its long-held restrictions in response to the coronavirus .\nThat \u2019 s good news , because continual access to two primary treatment medications , buprenorphine and methadone , is key : If patients miss a dose , they could go into withdrawal and turn to street drugs , risking overdose .\nThose struggling with addiction are particularly vulnerable in the age of coronavirus for a host of reasons . Opioid users have far higher rates of health conditions including hepatitis C , HIV , and chronic bronchitis . Many are well over the age of 60 . Infectious disease can spread like wildfire among communities of drug users ( think the HIV outbreak in Indiana in 2015 ) . And then there are the psychological factors : \u201c We all know that stress is one of the major triggers for people to go into relapse , \u201d said Bethany Hallam , an Allegheny County councilwoman and outspoken addiction treatment advocate . \u201c To think of all the additional stressors that people have in their lives right now , on top of the regular every day stressors\u2014and then you add into that people sitting at home stewing . \u201d\nAs Corey Davis , an attorney at the Network for Public Health Law , put it , \u201c We \u2019 re now facing two deadly , concurrent declared public health emergencies : the opioid crisis and COVID-19 . \u201d\nMethadone : Daily Trips to Clinics Will No Longer Be Required\nSome 350,000 Americans rely on methadone clinics for daily opioid addiction treatment , and , under normal circumstances , they \u2019 re required by law to take their doses at methadone clinics , where they often wait in long lines to take their doses in a supervised setting .\n\u201c We \u2019 re now facing two deadly , concurrent declared public health emergencies : the opioid crisis and COVID-19 . \u201d\nFederal guidance so far when it comes to methadone clinics during the pandemic has been confusing , to say the least . Until this week , the Substance Abuse and Mental Health Administration \u2019 s directed clinics to follow each state \u2019 s lead on a coronavirus response . On Monday , SAMHSA released two conflicting sets of guidelines for methadone clinics and patients . The first permitted a take-home supply of up to two weeks , but only if a methadone patient had coronavirus or symptoms of it , got a clinician to sign off , and applied with that sign-off to SAMHSA .\nBut separate guidance , also released Monday by SAMHSA , is much more lax , allowing for four weeks of take-home doses for stable patients\u2014with no state or federal sign-off required for each patient\u2014and two weeks for less-stable patients who the clinic believes \u201c can safely handle this level of take-home medication. \u201d This is the guidance that will hold during the pandemic , says SAMHSA spokesperson Christopher Garrett : Monday \u2019 s more restrictive guidelines were taken down this morning .\nThe coronavirus is putting pressure on an age-old controversy over just how much red tape should exist around opioid addiction treatment . Methadone is among America \u2019 s most highly regulated medications , relegated to special clinics rather than accessible at a typical doctor \u2019 s office . In theory , that \u2019 s because methadone is itself an opioid , but one that is meant to ease the cravings of opioid addiction without getting the patient high . The highly regulated setting is beneficial for some : The idea is that it ensures people aren \u2019 t abusing the medication or selling it on the street . But methadone advocates , including many leading public health experts , have long pushed for methadone to be treated just like any other medication : For now , the average doctor is allowed to prescribe a number of addictive opioids like OxyContin , Vicodin , or fentanyl , but isn \u2019 t allowed to prescribe methadone , the opioid addiction treatment .\nThe second primary opioid addiction treatment is buprenorphine , also itself an opioid , also to be taken daily , but treated more like a normal medication : Patients can go to doctors \u2019 offices for their prescriptions and pick up their medications from pharmacies .\nUntil Tuesday , one big concern about buprenorphine access was the requirement that providers meet prospective new patients for evaluations in person , rather than using telemedicine for the initial consultations . Given the push for social distancing and the overrun medical system , many feared that this rule would effectively prevent any new patients from being able to start buprenorphine . On Tuesday , DEA eased these restrictions : Now , initial consultations can be done virtually .\nThere are still a lot of restrictions around buprenorphine : Providers have to get special licenses from the DEA to prescribe the medication , and once they do , they can only prescribe it to a certain number of patients . Given the pandemic , some are advocating for an ease on the those caps : \u201c We don \u2019 t know what proportion of our prescriber population is going to fall ill , \u201d said Greg Marotta , president of Clean Slate , the nation \u2019 s largest office-based opioid treatment provider . \u201c For us to have to turn away patients because we don \u2019 t have the prescribing capacity available to us would be an absolute disaster . \u201d",
    "content_original": "For the hundreds of thousands of Americans who have to visit clinics for daily doses of opioid addiction medication, social distancing is nearly impossible. But on Tuesday, the federal government eased some of its long-held restrictions in response to the coronavirus.\n\nThat\u2019s good news, because continual access to two primary treatment medications, buprenorphine and methadone, is key: If patients miss a dose, they could go into withdrawal and turn to street drugs, risking overdose.\n\nThose struggling with addiction are particularly vulnerable in the age of coronavirus for a host of reasons. Opioid users have far higher rates of health conditions including hepatitis C, HIV, and chronic bronchitis. Many are well over the age of 60. Infectious disease can spread like wildfire among communities of drug users (think the HIV outbreak in Indiana in 2015). And then there are the psychological factors: \u201cWe all know that stress is one of the major triggers for people to go into relapse,\u201d said Bethany Hallam, an Allegheny County councilwoman and outspoken addiction treatment advocate. \u201cTo think of all the additional stressors that people have in their lives right now, on top of the regular every day stressors\u2014and then you add into that people sitting at home stewing.\u201d\n\nAs Corey Davis, an attorney at the Network for Public Health Law, put it, \u201cWe\u2019re now facing two deadly, concurrent declared public health emergencies: the opioid crisis and COVID-19.\u201d\n\nMethadone: Daily Trips to Clinics Will No Longer Be Required\n\nSome 350,000 Americans rely on methadone clinics for daily opioid addiction treatment, and, under normal circumstances, they\u2019re required by law to take their doses at methadone clinics, where they often wait in long lines to take their doses in a supervised setting.\n\n\u201cWe\u2019re now facing two deadly, concurrent declared public health emergencies: the opioid crisis and COVID-19.\u201d\n\nFederal guidance so far when it comes to methadone clinics during the pandemic has been confusing, to say the least. Until this week, the Substance Abuse and Mental Health Administration\u2019s directed clinics to follow each state\u2019s lead on a coronavirus response. On Monday, SAMHSA released two conflicting sets of guidelines for methadone clinics and patients. The first permitted a take-home supply of up to two weeks, but only if a methadone patient had coronavirus or symptoms of it, got a clinician to sign off, and applied with that sign-off to SAMHSA.\n\nBut separate guidance, also released Monday by SAMHSA, is much more lax, allowing for four weeks of take-home doses for stable patients\u2014with no state or federal sign-off required for each patient\u2014and two weeks for less-stable patients who the clinic believes \u201ccan safely handle this level of take-home medication.\u201d This is the guidance that will hold during the pandemic, says SAMHSA spokesperson Christopher Garrett: Monday\u2019s more restrictive guidelines were taken down this morning.\n\nThe coronavirus is putting pressure on an age-old controversy over just how much red tape should exist around opioid addiction treatment. Methadone is among America\u2019s most highly regulated medications, relegated to special clinics rather than accessible at a typical doctor\u2019s office. In theory, that\u2019s because methadone is itself an opioid, but one that is meant to ease the cravings of opioid addiction without getting the patient high. The highly regulated setting is beneficial for some: The idea is that it ensures people aren\u2019t abusing the medication or selling it on the street. But methadone advocates, including many leading public health experts, have long pushed for methadone to be treated just like any other medication: For now, the average doctor is allowed to prescribe a number of addictive opioids like OxyContin, Vicodin, or fentanyl, but isn\u2019t allowed to prescribe methadone, the opioid addiction treatment.\n\nBuprenorphine: In-Person Requirements Will Be Eased\n\nThe second primary opioid addiction treatment is buprenorphine, also itself an opioid, also to be taken daily, but treated more like a normal medication: Patients can go to doctors\u2019 offices for their prescriptions and pick up their medications from pharmacies.\n\nUntil Tuesday, one big concern about buprenorphine access was the requirement that providers meet prospective new patients for evaluations in person, rather than using telemedicine for the initial consultations. Given the push for social distancing and the overrun medical system, many feared that this rule would effectively prevent any new patients from being able to start buprenorphine. On Tuesday, DEA eased these restrictions: Now, initial consultations can be done virtually.\n\nThere are still a lot of restrictions around buprenorphine: Providers have to get special licenses from the DEA to prescribe the medication, and once they do, they can only prescribe it to a certain number of patients. Given the pandemic, some are advocating for an ease on the those caps: \u201cWe don\u2019t know what proportion of our prescriber population is going to fall ill,\u201d said Greg Marotta, president of Clean Slate, the nation\u2019s largest office-based opioid treatment provider. \u201cFor us to have to turn away patients because we don\u2019t have the prescribing capacity available to us would be an absolute disaster.\u201d",
    "source_url": "www.motherjones.com",
    "bias_text": "left",
    "ID": "jeYeP447QW0Bdo6o"
}